Role of Reactive Oxygen and Nitrogen Species in Olfactory Epithelial Injury by the Sulfur Mustard Analogue 2-Chloroethyl Ethyl Sulfide

Department of Pharmaceutical Sciences, University of Colorado at Denver Health Sciences Center, Denver, USA.
American Journal of Respiratory Cell and Molecular Biology (Impact Factor: 3.99). 06/2011; 45(2):323-31. DOI: 10.1165/rcmb.2010-0214OC
Source: PubMed


The inhalation of sulfur mustard (SM) causes substantial deposition in the nasal region. However, specific injury has not been characterized. 2-chloroethyl ethyl sulfide (CEES) is an SM analogue used to model injury and screen potential therapeutics. After the inhalation of CEES, damage to the olfactory epithelium (OE) was extensive. Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling-positive cells were present by 4 hours, and maximal at 18-72 hours. Cleaved caspase 3 immunohistochemistry (IHC) was maximal at 18 hours after the inhalation of 5% CEES. Olfactory marker protein (OMP)-positive olfactory neurons were markedly decreased at 18 hours. IHC-positive cells for 3-nitrotyrosine (3-NT) within epithelium were elevated by 8 hours, waning by 18 hours, and absent by 72 hours. AEOL 10150, a catalytic manganoporphyrin antioxidant, administered both subcutaneously (5 mg/kg) and intranasally (50 μM, "combined treatment"), decreased OE injury. CEES-induced increases in markers of cell death were decreased by combined treatment involving AEOL 10150. CEES-induced changes in OMP and 3-NT immunostaining were markedly improved by combined treatment involving AEOL 10150. The selective inducible nitric oxide synthase inhibitor 1400W (5 mg/kg, subcutaneous), administered 1 hour after inhalation and thereafter every 4 hours (five doses), also reduced OE damage with improved OMP and 3-NT staining. Taken together, these data indicate that reactive oxygen and nitrogen species are important mediators in CEES-induced nasal injury.

Download full-text


Available from: Brian J Day,
  • Source
    • "There currently is no established antidote for inhalational HD exposure (Papirmeister, Feister, Robinson, & Ford, 2000; U.S. Army Medical Research Institute of Chemical Defense, 2007) though several therapeutic approaches are currently under investigation (Anderson, Byers, & Vesely, 2000; Anderson, Taylor, Fetterer, & Holmes, 2009; Jugg et al., 2013; O'Neill et al., 2010; O'Neill et al., 2011; Papirmeister et al., 2000; Rancourt et al., 2012; Veress et al., 2013). In order to properly evaluate the efficacy of potential treatments for this route of exposure, animal models that accurately replicate the physiological injuries induced by HD inhalation are needed. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction A custom designed HD exposure system was used to deliver controlled inhaled doses to an animal model through an endotracheal tube. Methods Target HD vapor challenges were generated by a temperature controlled bubbler/aerosol trap, while concentration was monitored near real-time by gas chromatography. Animal breathing parameters were monitored real-time by an in-line pneumotach, pressure transducer, and Buxco pulmonary analysis computer/software. For each exposure, the challenge atmosphere was allowed to stabilize at the desired concentration while the anesthetized animal was provided humidity controlled clean air. Once the target concentration was achieved and stable, a portion of the challenge atmosphere was drawn past the endotracheal tube, where the animal inhaled the exposure ad libitum. During the exposure, HD vapor concentration and animal weight were used to calculate the needed inhaled volume to achieve the target inhaled dose (μg/kg). The exposures were halted when the inhaled volume was achieved. Results The exposure system successfully controlled HD concentrations from 22.2 to 278 mg/m3 and accurately delivered inhaled doses between 49.3 and 1120 μg/kg with actual administered doses being within 4% of the target level. Discussion This exposure system administers specific HD inhaled doses to evaluate physiological effects and for evaluation of potential medical countermeasure treatments.
    Journal of Pharmacological and Toxicological Methods 10/2014; 71. DOI:10.1016/j.vascn.2014.09.009 · 2.39 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Based on aqueous redox chemistry and simple in vivo models of oxidative stress, Escherichia coli and Saccharomyces cerevisiae, the cationic Mn(III) N-substituted pyridylporphyrins (MnPs) have been identified as the most potent cellular redox modulators within the porphyrin class of drugs; their efficacy in animal models of diseases that have oxidative stress in common is based on their high ability to catalytically remove superoxide, peroxynitrite, carbonate anion radical, hypochlorite, nitric oxide, lipid peroxyl and alkoxyl radicals, thus suppressing the primary oxidative event. While doing so MnPs could couple with cellular reductants and redox-active proteins. Reactive species are widely accepted as regulators of cellular transcriptional activity: minute, nanomolar levels are essential for normal cell function, while submicromolar or micromolar levels impose oxidative stress, which is evidenced in increased inflammatory and immune responses. By removing reactive species, MnPs affect redox-based cellular transcriptional activity and consequently secondary oxidative stress, and in turn inflammatory processes. The equal ability to reduce and oxidize superoxide during the dismutation process and recently accumulated results suggest that pro-oxidative actions of MnPs may also contribute to their therapeutic effects. All our data identify the superoxide dismutase-like activity, estimated by log k(cat)(O(2)(-)), as a good measure for the therapeutic efficacy of MnPs. Their accumulation in mitochondria and their ability to cross the blood-brain barrier contribute to their remarkable efficacy. We summarize herein the therapeutic effects of MnPs in cancer, central nervous system injuries, diabetes, their radioprotective action and potential for imaging. Few of the most potent modulators of cellular redox-based pathways, MnTE2-PyP(5+), MnTDE-2-ImP(5+), MnTnHex-2-PyP(5+) and MnTnBuOE-2-PyP(5+), are under preclinical and clinical development.
    Medical Principles and Practice 10/2012; 22(2). DOI:10.1159/000341715 · 1.34 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Rationale: Plastic bronchitis is a rare but life-threatening disorder characterized by bronchial cast formation, resulting in severe airway obstruction that leads to respiratory failure and/or death. Mortality rate approaches 60%. Current therapies are anecdotal, due to lack of systematic research available to assess efficacy of therapies in regards to improvements in either mortality and/or morbidity. Methods: Adult rats exposed to sulfur mustard analog were treated with intratracheal tPA (0.15-0.7mg/kg, 5.5 and 6.5 h), compared to controls (no treatment, isoflurane, and placebo). Respiratory distress and pulse oximetry were assessed (for 12 or 48 h), and arterial blood gases were obtained at study termination (12 h). Microdissection of fixed lungs was done to assess airway obstruction by casts. Results: Optimal intratracheal tPA treatment (0.7mg/kg) completely eliminated mortality (0% at 48 h) and greatly improved morbidity in this nearly uniformly fatal disease model (90-100% mortality at 48 h). tPA normalized plastic bronchitis-associated hypoxemia, hypercarbia, and lactic acidosis, and improved respiratory distress (i.e. clinical scores) while decreasing airway fibrin casts. Conclusions: Intratracheal tPA diminished airway obstructive fibrin-containing casts while improving clinical respiratory distress, pulmonary gas exchange, tissue oxygenation, and oxygen utilization in our model of severe plastic bronchitis. Most importantly, mortality, which was associated with hypoxemia and clinical respiratory distress, was eliminated.
    American Journal of Respiratory Cell and Molecular Biology 12/2012; 48(4). DOI:10.1165/rcmb.2012-0177OC · 3.99 Impact Factor
Show more